You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 11, November 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Diabetic Retinopathy
 •Articles for Residents
 •Endocrine Diseases
 •Diabetes Mellitus
 •Hypertension
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Risks of Progression of Retinopathy and Vision Loss Related to Tight Blood Pressure Control in Type 2 Diabetes Mellitus

UKPDS 69

UK Prospective Diabetes Study (UKPDS) Group*

Arch Ophthalmol. 2004;122:1631-1640.

Objective  To determine the relationship between tight blood pressure (BP) control and the different aspects of diabetic retinopathy in patients with type 2 diabetes mellitus (DM).

Setting  Nineteen hospital-based clinics in England, Scotland, and Northern Ireland.

Design  Outcome of retinopathy status assessed by 4-field retinal photography related to allocation within a randomized controlled trial comparing a tight BP control policy aiming for a BP less than 150/85 mm Hg with a less tight BP control policy aiming for a BP less than 180/105 mm Hg.

Subjects  One thousand one hundred forty-eight hypertensive patients with type 2 DM were studied. These patients had type 2 DM for a mean duration of 2.6 years at the inception of the Hypertension in Diabetes Study, had a mean age of 56 years; and had a mean BP of 160/94 mm Hg. Seven hundred fifty-eight patients were allocated to a tight BP control policy with angiotensin-converting enzyme inhibitor or {beta}-blockers as the main therapy; 390 were allocated to a less tight BP control policy.

Main Outcome Measures  Deterioration of retinopathy (≥2-step change on a modified Early Treatment Diabetic Retinopathy Study [ETDRS] final scale), together with end points (photocoagulation, vitreous hemorrhage, and cataract extraction) and analysis of specific lesions (microaneurysms, hard exudates, and cotton-wool spots). Visual acuity was assessed at 3-year intervals using ETDRS logarithm of the minimum angle of resolution charts. Blindness was monitored as an end point with the criterion of Snellen chart assessment at 6/60 or worse.

Results  By 4.5 years after randomization, there was a highly significant difference in microaneurysm count with 23.3% in the tight BP control group and 33.5% in the less tight BP control group having 5 or more microaneurysms (relative risk [RR], 0.70; P = .003). The effect continued to 7.5 years (RR, 0.66; P<.001). Hard exudates increased from a prevalence of 11.2% to 18.3% at 7.5 years after randomization with fewer lesions found in the tight BP control group (RR, 0.53; P<.001). Cotton-wool spots increased in both groups but less so in the tight BP control group which had fewer cotton-wool spots at 7.5 years (RR, 0.53; P<.001). A 2-step or more deterioration on the ETDRS scale was significantly different at 4.5 years with fewer people in the tight BP control group progressing 2 steps or more (RR, 0.75; P = .02). Patients allocated to tight BP control were less likely to undergo photocoagulation (RR, 0.65; P = .03). This difference was driven by a difference in photocoagulation due to maculopathy (RR, 0.58; P = .02). The cumulative incidence of the end point of blindness (Snellen visual acuity, ≥6/60) in 1 eye was 18/758 for the tight BP control group compared with 12/390 for less tight BP control group. These equate to absolute risks of 3.1 to 4.1 per 1000 patient-years, respectively (P = .046; RR, 0.76; 99% confidence interval, 0.29-1.99). There was no detectable difference in outcome between the 2 randomized therapies of angiotensin-converting enzyme inhibition and {beta}-blockade.

Conclusions  High BP is detrimental to each aspect of diabetic retinopathy; a tight BP control policy reduces the risk of clinical complications from diabetic eye disease.



*Authors: This report was prepared on behalf of the UKPDS by David R. Matthews, FRCP; Irene M. Stratton, BS, MSc; Stephen J. Aldington, DMS; Rury R. Holman, FRCP; Eva M. Kohner, FRCP.
Group Information: A list of the UKPDS Group as of September 17, 2004, was published in Lancet. 1998;352:837-853.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Is Intensive Management of Blood Pressure to Prevent Visual Loss in Persons With Type 2 Diabetes Indicated?
Ronald Klein
Arch Ophthalmol. 2004;122(11):1707-1709.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prediction of Incident Stroke Events Based on Retinal Vessel Caliber: A Systematic Review and Individual-Participant Meta-Analysis
McGeechan et al.
Am J Epidemiol 2009;170:1323-1332.
ABSTRACT | FULL TEXT  

Meta-analysis: Retinal Vessel Caliber and Risk for Coronary Heart Disease
McGeechan et al.
ANN INTERN MED 2009;151:404-413.
ABSTRACT | FULL TEXT  

Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes
Mauer et al.
NEJM 2009;361:40-51.
ABSTRACT | FULL TEXT  

Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability
Phipps et al.
Hypertension 2009;53:175-181.
ABSTRACT | FULL TEXT  

Changes in Incidence of Diabetes Mellitus-Related Eye Disease Among US Elderly Persons, 1994-2005
Sloan et al.
Arch Ophthalmol 2008;126:1548-1553.
ABSTRACT | FULL TEXT  

Quality of diabetes care among patients managed by teleconsultation
Nikkanen et al.
J Telemed Telecare 2008;14:295-299.
ABSTRACT | FULL TEXT  

Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study
Gallego et al.
BMJ 2008;337:a918-a918.
ABSTRACT | FULL TEXT  

Retinal Vascular Lesions in Patients of Caucasian and Asian Origin With Type 2 Diabetes: Baseline results from the ADVANCE Retinal Measurements (AdRem) study
Stolk et al.
Diabetes Care 2008;31:708-713.
ABSTRACT | FULL TEXT  

Effect of Board Certification on Antihypertensive Treatment Intensification in Patients With Diabetes Mellitus
Turchin et al.
Circulation 2008;117:623-628.
ABSTRACT | FULL TEXT  

Preventing and managing diabetic complications in elderly patients
HORNICK and ARON
Cleveland Clinic Journal of Medicine 2008;75:153-158.
ABSTRACT | FULL TEXT  

Screening for and managing diabetic retinopathy: Current approaches
Bloomgarden
Am J Health Syst Pharm 2007;64:S8-S14.
ABSTRACT | FULL TEXT  

Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT | FULL TEXT  

Role of Nonproteolytically Activated Prorenin in Pathologic, but Not Physiologic, Retinal Neovascularization
Satofuka et al.
IOVS 2007;48:422-429.
ABSTRACT | FULL TEXT  

Retinal Hemodynamics in Early Diabetic Macular Edema
Guan et al.
Diabetes 2006;55:813-818.
ABSTRACT | FULL TEXT  

Circadian Fluctuations of Macular Edema in Patients with Morning Vision Blurring: Correlation with Arterial Pressure and Effect of Light Deprivation
Paques et al.
IOVS 2005;46:4707-4711.
ABSTRACT | FULL TEXT  

Hypertensive retinopathy revisited: some answers, more questions
Grosso et al.
Br J Ophthalmol 2005;89:1646-1654.
ABSTRACT | FULL TEXT  

Is Intensive Management of Blood Pressure to Prevent Visual Loss in Persons With Type 2 Diabetes Indicated?
Klein
Arch Ophthalmol 2004;122:1707-1709.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.